Xeris Biopharma
XERS
Xeris Biopharma (XERS) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $12.00 from $9.00 | Aug 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Mar 2, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Jan 9, 2026 |
| Barclays | Initiated Coverage | Overweight | $9.00 | Dec 9, 2025 |
| Piper Sandler | Maintained | Neutral | $8.00 from $6.00 | Nov 7, 2025 |
| Oppenheimer | Maintained | Outperform | $18.00 | Nov 7, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Nov 7, 2025 |
| Oppenheimer | Maintained | Outperform | $18.00 from $8.00 | Oct 29, 2025 |
| Leerink Partners | Maintained | Outperform | $9.00 from $7.00 | Aug 19, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $10.00 | Aug 12, 2025 |
| Oppenheimer | Maintained | Outperform | $7.00 from $6.00 | May 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $8.00 from $6.60 | Mar 7, 2025 |
| Piper Sandler | Maintained | Neutral | $4.00 from $3.00 | Mar 7, 2025 |
| Craig-Hallum | Maintained | Buy | $6.50 from $5.00 | Mar 7, 2025 |
| Leerink Partners | Maintained | Outperform | $6.00 from $5.00 | Mar 7, 2025 |
| Jefferies | Maintained | Buy | $6.00 from $4.00 | Jan 29, 2025 |
| Piper Sandler | Downgraded | Overweight → Neutral | $3.00 | Nov 11, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $6.60 from $6.00 | Nov 11, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $6.00 | Aug 15, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $6.00 | May 31, 2024 |
Frequently asked questions
What is the latest analyst rating on XERS?
On Aug 20, 2026, Barclays maintained Xeris Biopharma at Overweight with a price target of $12.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.